San Diego, CA--June 9, 2011--Mentor Capital, Inc. (Pink Sheets:MNTR) CEO, Chester Billingsley, reported that he has made cash purchases of an additional 3.14% of outstanding Mentor Capital stock during 2011 at an average share price of $0.68 per share.

Mr. Billingsley emphasizes, “Mentor Capital only has 2.2 Million shares issued and outstanding on both a basic and diluted basis. Some stock feeds erroneously report Mentor shares at 11 Million. The incorrect stock issued figure overstates shares and understates value by a factor of 5x. Being absolutely certain that the low number of shares officially reported by Mentor Capital, Inc. is correct at 2.2 Million is an important part of any stock purchase decision.”

Mentor Capital, only acquires and invests in cancer related companies. The company currently holds $2.50 per Mentor Capital share in cancer assets from twelve companies. Management seeks to weight its investments so that shareholders support the best medical science in the battle against cancer. Typical cancer investments can be tracked through updates and summaries of the several smaller stock purchases made across the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.


__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top